Loading stock data…
$39.56+0.44 (+1.12%)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Sanofi in the Healthcare sector is trading at $39.12 with a market capitalization of $104.1B. Wall Street consensus targets $53.61 (9 analysts), implying a +37.0% move over the next 12 months. The stock is currently near its 52-week low of $39.07, remaining 10.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.30B↑ | $11.24B↓ | $12.21B↓ | $13.17B↑ | $10.73B |
| Gross Profit | $9.28B↑ | $8.11B↓ | $8.45B↓ | $9.76B↑ | $7.74B |
| Operating Income | $2.38B↑ | $2.27B↑ | $1.63B↓ | $3.79B↑ | $1.71B |
| Net Income | $343.00M↓ | $1.61B↑ | -$801.00M↓ | $2.80B↓ | $3.94B |
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...